Apollomics (NASDAQ:APLM) CEO Hung-Wen Chen Acquires 266,667 Shares of Stock

Apollomics Inc. (NASDAQ:APLM) CEO Hung-Wen Chen acquired 266,667 shares of Apollomics stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $15.00 per share, with a total value of $4,000,005.00. Following the completion of the transaction, the chief executive officer owned 1,029,695 shares of the company’s stock, valued at approximately $15,445,425. This trade represents a 34.95% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Hung-Wen Chen also recently made the following trade(s):

• On Friday, August 14th, Hung-Wen Chen acquired 270,000 shares of Apollomics stock. The stock was bought at an average price of $13.15 per share, for a total transaction of $3,550,500.00.

Apollomics Price Performance

Shares of APLM traded down $0.04 during trading hours on Monday, hitting $23.36. The company had a trading volume of 35,072 shares, compared to its average volume of 30,338. The business has a fifty day moving average of $18.24 and a 200-day moving average of $17.30. Apollomics Inc. has a 12 month low of $3.66 and a 12 month high of $42.12.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Apollomics currently has an average rating of “Sell”.

Institutional Trading of Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC acquired a new position in shares of Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics at the end of the most recent reporting period. Institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.